Prof. Andrew Scott leads the Tumour Targeting Laboratory at the Olivia Newton-John Cancer Research Institute, is the co-Director of the Centre for Research Excellence in Brain Cancer, is the Director of the Department of Molecular Imaging and Therapy, Austin Health, and holds Professorial positions at La Trobe University and The University of Melbourne. 

Andrew’s clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer (particularly with monoclonal antibodies), molecular imaging in oncology, and global advocacy in oncology and nuclear medicine. Andrew’s laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies, and have entered Phase I/II/III trials. He has published over 496 peer reviewed papers and 27 book chapters, is an inventor on 26 patents, and is a founder of a biotech company. 

Andrew is actively involved in the training and mentoring of young scientists and clinicians, and is currently supervising several doctoral students, postdoctoral fellows and nuclear medicine trainees. Another focus of his work is strategic planning for training, health care policy, and molecular imaging and nuclear medicine therapy advocacy within the US, European, South American, Asia-Oceania, and African regions, as well as with the IAEA and WHO.  Andrew also participates in policy and governance activities with the Australian Government.